No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ACAD240419C23000
- 0.13
- 0.000.00%
15min DelayClose Mar 19 10:20 ET
0.00High0.00Low
0.00Open0.13Pre Close0 Volume0 Open Interest23.00Strike Price0.00Turnover3191.45%IV38.42%PremiumApr 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-7DDays to Expiry0.13Time Value100Contract SizeAmericanOptions Type0.0860Delta0.0439Gamma128.54Leverage Ratio-16.7890Theta0.0000Rho11.05Eff Leverage0.0002Vega
Intraday
- 5D
- 1D
News
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
ACADIA Pharmaceuticals (NASDAQ:ACAD) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares sinc
Express News | Acadia Pharmaceuticals Announces Trofinetide New Drug Submission For Treatment Of Rett Syndrome Accepted For Filing And Priority Review By Health Canada
Express News | ACADIA Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock
Express News | ACADIA Pharmaceuticals Inc : Needham Cuts Target Price to $30 From $32: Needham Cuts Target Price to $30 From $32
Comments
Analysts have high confidence in ACADIA Pharmaceuticals, predicting an average annual growth rate of 42%. The company's lack of debt reduces concerns around repayments and makes it a less risky investment.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) On The Verge Of Breaking Even 1
Several companies were in the spotlight due to various developments:
Oracle ( $Oracle(ORCL.US$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $ACADIA Pharmaceuticals(ACAD.US$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts(MTN.US$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$Asana(ASAN.US$ Asana rep...
Oracle ( $Oracle(ORCL.US$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $ACADIA Pharmaceuticals(ACAD.US$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts(MTN.US$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$Asana(ASAN.US$ Asana rep...
2
$ACADIA Pharmaceuticals(ACAD.US$ And where will the bottom be? Could it be a opportunity? Time will tell? Hehehe
Ouch! I’m seeing a drop coming?
$ACADIA Pharmaceuticals(ACAD.US$ Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effe...
1
6
Read more